Skip to main content
Top
Published in: Molecular Cancer 1/2005

Open Access 01-12-2005 | Short communication

Inactivation of MAP kinase signalling in Myc Transformed Cells and Rescue by LiCl inhibition of GSK3

Authors: Osama Al-Assar, Dorothy H Crouch

Published in: Molecular Cancer | Issue 1/2005

Login to get access

Abstract

c-Myc oncogene is an important regulator of cell cycle and apoptosis, and its dysregulated expression is associated with many malignancies. Myc is instrumental in directly or indirectly regulating the progression through the G1 phase and G1/S transition, and transformation by Myc results in perturbed cell cycle. Also contributory to the control of G1 is the Ras effector pathway Raf/MEK/ERK MAP kinase. Together with GSK3, ERK plays an important role in the critical hierarchical phosphorylation of S62/T58 controlling Myc protein levels. Therefore, our main aim was to examine the levels of MAPK in Myc transformed cells in light of the roles of ERK in cell cycle and control of Myc protein levels. We found that active forms of ERK were barely detectable in v-Myc (MC29) transformed cells. Furthermore, we could only detect reduced levels of activated ERK in c-Myc transformed cells compared to the non-transformed primary chick embryo fibroblast cells. The addition of LiCl inhibited GSK3 and successfully restored the levels of ERK in v-Myc and c-Myc transformed cells to those found in non-transformed cells. In addition, LiCl stabilised Myc protein in the non-transformed and c-Myc transformed cells but not in v-Myc transformed cells. These results can provide an important insight into the role of MAPK in the mechanism of Myc induced transformation and carcinogenesis.
Appendix
Available only for authorised users
Literature
2.
go back to reference Nesbit CE, Tersak JM, Prochownik EV: MYC oncogenes and human neoplastic disease. Oncogene. 1999, 18: 3004-3016. 10.1038/sj.onc.1202746CrossRefPubMed Nesbit CE, Tersak JM, Prochownik EV: MYC oncogenes and human neoplastic disease. Oncogene. 1999, 18: 3004-3016. 10.1038/sj.onc.1202746CrossRefPubMed
4.
go back to reference Bouchard C, Staller P, Eilers M: Control of cell proliferation by Myc. Trends Cell Biol. 1998, 8: 202-206. 10.1016/S0962-8924(98)01251-3CrossRefPubMed Bouchard C, Staller P, Eilers M: Control of cell proliferation by Myc. Trends Cell Biol. 1998, 8: 202-206. 10.1016/S0962-8924(98)01251-3CrossRefPubMed
5.
go back to reference Watson JD, Oster SK, Shago M, Khosravi F, Penn LZ: Identifying genes regulated in a Myc-dependent manner. J Biol Chem. 2002, 277: 36921-36930. 10.1074/jbc.M201493200CrossRefPubMed Watson JD, Oster SK, Shago M, Khosravi F, Penn LZ: Identifying genes regulated in a Myc-dependent manner. J Biol Chem. 2002, 277: 36921-36930. 10.1074/jbc.M201493200CrossRefPubMed
6.
go back to reference Menssen A, Hermeking H: Characterization of the c-MYC-regulated transcriptome by SAGE: identification and analysis of c-MYC target genes. Proc Natl Acad Sci U S A. 2002, 99: 6274-6279. 10.1073/pnas.082005599PubMedCentralCrossRefPubMed Menssen A, Hermeking H: Characterization of the c-MYC-regulated transcriptome by SAGE: identification and analysis of c-MYC target genes. Proc Natl Acad Sci U S A. 2002, 99: 6274-6279. 10.1073/pnas.082005599PubMedCentralCrossRefPubMed
7.
go back to reference Blackwood EM, Eisenman RN: Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc. Science. 1991, 251: 1211-1217.CrossRefPubMed Blackwood EM, Eisenman RN: Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc. Science. 1991, 251: 1211-1217.CrossRefPubMed
8.
go back to reference Amati B, Dalton S, Brooks MW, Littlewood TD, Evan GI, Land H: Transcriptional activation by the human c-Myc oncoprotein in yeast requires interaction with Max. Nature. 1992, 359: 423-426. 10.1038/359423a0CrossRefPubMed Amati B, Dalton S, Brooks MW, Littlewood TD, Evan GI, Land H: Transcriptional activation by the human c-Myc oncoprotein in yeast requires interaction with Max. Nature. 1992, 359: 423-426. 10.1038/359423a0CrossRefPubMed
9.
go back to reference Prendergast GC, Lawe D, Ziff EB: Association of Myn, the murine homolog of max, with c-Myc stimulates methylation-sensitive DNA binding and ras cotransformation. Cell. 1991, 65: 395-407. 10.1016/0092-8674(91)90457-ACrossRefPubMed Prendergast GC, Lawe D, Ziff EB: Association of Myn, the murine homolog of max, with c-Myc stimulates methylation-sensitive DNA binding and ras cotransformation. Cell. 1991, 65: 395-407. 10.1016/0092-8674(91)90457-ACrossRefPubMed
10.
go back to reference Flinn EM, Busch CM, Wright AP: myc boxes, which are conserved in myc family proteins, are signals for protein degradation via the proteasome. Mol Cell Biol. 1998, 18: 5961-5969.PubMedCentralPubMed Flinn EM, Busch CM, Wright AP: myc boxes, which are conserved in myc family proteins, are signals for protein degradation via the proteasome. Mol Cell Biol. 1998, 18: 5961-5969.PubMedCentralPubMed
11.
12.
go back to reference Lutterbach B, Hann SR: Hierarchical phosphorylation at N-terminal transformation-sensitive sites in c-Myc protein is regulated by mitogens and in mitosis. Mol Cell Biol. 1994, 14: 5510-5522.PubMedCentralPubMed Lutterbach B, Hann SR: Hierarchical phosphorylation at N-terminal transformation-sensitive sites in c-Myc protein is regulated by mitogens and in mitosis. Mol Cell Biol. 1994, 14: 5510-5522.PubMedCentralPubMed
13.
go back to reference Lutterbach B, Hann SR: c-Myc transactivation domain-associated kinases: questionable role for map kinases in c-Myc phosphorylation. J Cell Biochem. 1999, 72: 483-491. 10.1002/(SICI)1097-4644(19990315)72:4<483::AID-JCB4>3.0.CO;2-ICrossRefPubMed Lutterbach B, Hann SR: c-Myc transactivation domain-associated kinases: questionable role for map kinases in c-Myc phosphorylation. J Cell Biochem. 1999, 72: 483-491. 10.1002/(SICI)1097-4644(19990315)72:4<483::AID-JCB4>3.0.CO;2-ICrossRefPubMed
14.
go back to reference Hancock JF: Ras proteins: different signals from different locations. Nat Rev Mol Cell Biol. 2003, 4: 373-384. 10.1038/nrm1105CrossRefPubMed Hancock JF: Ras proteins: different signals from different locations. Nat Rev Mol Cell Biol. 2003, 4: 373-384. 10.1038/nrm1105CrossRefPubMed
15.
go back to reference Kimmelman AC, Osada M, Chan AM: R-Ras3, a brain-specific Ras-related protein, activates Akt and promotes cell survival in PC12 cells. Oncogene. 2000, 19: 2014-2022. 10.1038/sj.onc.1203530CrossRefPubMed Kimmelman AC, Osada M, Chan AM: R-Ras3, a brain-specific Ras-related protein, activates Akt and promotes cell survival in PC12 cells. Oncogene. 2000, 19: 2014-2022. 10.1038/sj.onc.1203530CrossRefPubMed
16.
go back to reference Yan J, Roy S, Apolloni A, Lane A, Hancock JF: Ras isoforms vary in their ability to activate Raf-1 and phosphoinositide 3-kinase. J Biol Chem. 1998, 273: 24052-24056. 10.1074/jbc.273.37.24052CrossRefPubMed Yan J, Roy S, Apolloni A, Lane A, Hancock JF: Ras isoforms vary in their ability to activate Raf-1 and phosphoinositide 3-kinase. J Biol Chem. 1998, 273: 24052-24056. 10.1074/jbc.273.37.24052CrossRefPubMed
17.
go back to reference Voice JK, Klemke RL, Le A, Jackson JH: Four human ras homologs differ in their abilities to activate Raf-1, induce transformation, and stimulate cell motility. J Biol Chem. 1999, 274: 17164-17170. 10.1074/jbc.274.24.17164CrossRefPubMed Voice JK, Klemke RL, Le A, Jackson JH: Four human ras homologs differ in their abilities to activate Raf-1, induce transformation, and stimulate cell motility. J Biol Chem. 1999, 274: 17164-17170. 10.1074/jbc.274.24.17164CrossRefPubMed
18.
go back to reference Self AJ, Caron E, Paterson HF, Hall A: Analysis of R-Ras signalling pathways. J Cell Sci. 2001, 114: 1357-1366.PubMed Self AJ, Caron E, Paterson HF, Hall A: Analysis of R-Ras signalling pathways. J Cell Sci. 2001, 114: 1357-1366.PubMed
19.
go back to reference Kauffmann-Zeh A, Rodriguez-Viciana P, Ulrich E, Gilbert C, Coffer P, Downward J, Evan G: Suppression of c-Myc-induced apoptosis by Ras signalling through PI(3)K and PKB. Nature. 1997, 385: 544-548. 10.1038/385544a0CrossRefPubMed Kauffmann-Zeh A, Rodriguez-Viciana P, Ulrich E, Gilbert C, Coffer P, Downward J, Evan G: Suppression of c-Myc-induced apoptosis by Ras signalling through PI(3)K and PKB. Nature. 1997, 385: 544-548. 10.1038/385544a0CrossRefPubMed
20.
go back to reference Lee HY, Srinivas H, Xia D, Lu Y, Superty R, LaPushin R, Gomez-Manzano C, Gal AM, Walsh GL, Force T, Ueki K, Mills GB, Kurie JM: Evidence That Phosphatidylinositol 3-Kinase- and Mitogen-activated Protein Kinase Kinase-4/c-Jun NH2-terminal Kinase-dependent Pathways Cooperate to Maintain Lung Cancer Cell Survival. J Biol Chem. 2003, 278: 23630-23638. 10.1074/jbc.M300997200CrossRefPubMed Lee HY, Srinivas H, Xia D, Lu Y, Superty R, LaPushin R, Gomez-Manzano C, Gal AM, Walsh GL, Force T, Ueki K, Mills GB, Kurie JM: Evidence That Phosphatidylinositol 3-Kinase- and Mitogen-activated Protein Kinase Kinase-4/c-Jun NH2-terminal Kinase-dependent Pathways Cooperate to Maintain Lung Cancer Cell Survival. J Biol Chem. 2003, 278: 23630-23638. 10.1074/jbc.M300997200CrossRefPubMed
21.
go back to reference Chang L, Karin M: Mammalian MAP kinase signalling cascades. Nature. 2001, 410: 37-40. 10.1038/35065000CrossRefPubMed Chang L, Karin M: Mammalian MAP kinase signalling cascades. Nature. 2001, 410: 37-40. 10.1038/35065000CrossRefPubMed
22.
go back to reference Morgan MA, Dolp O, Reuter CW: Cell-cycle-dependent activation of mitogen-activated protein kinase kinase (MEK-1/2) in myeloid leukemia cell lines and induction of growth inhibition and apoptosis by inhibitors of RAS signaling. Blood. 2001, 97: 1823-1834. 10.1182/blood.V97.6.1823CrossRefPubMed Morgan MA, Dolp O, Reuter CW: Cell-cycle-dependent activation of mitogen-activated protein kinase kinase (MEK-1/2) in myeloid leukemia cell lines and induction of growth inhibition and apoptosis by inhibitors of RAS signaling. Blood. 2001, 97: 1823-1834. 10.1182/blood.V97.6.1823CrossRefPubMed
23.
go back to reference Zheng B, Fiumara P, Li YV, Georgakis G, Snell V, Younes M, Vauthey JN, Carbone A, Younes A: MEK/ERK pathway is aberrantly active in Hodgkin disease: a signaling pathway shared by CD30, CD40, and RANK that regulates cell proliferation and survival. Blood. 2003, 102: 1019-1027. 10.1182/blood-2002-11-3507CrossRefPubMed Zheng B, Fiumara P, Li YV, Georgakis G, Snell V, Younes M, Vauthey JN, Carbone A, Younes A: MEK/ERK pathway is aberrantly active in Hodgkin disease: a signaling pathway shared by CD30, CD40, and RANK that regulates cell proliferation and survival. Blood. 2003, 102: 1019-1027. 10.1182/blood-2002-11-3507CrossRefPubMed
24.
go back to reference Fincham VJ, James M, Frame MC, Winder SJ: Active ERK/MAP kinase is targeted to newly forming cell-matrix adhesions by integrin engagement and v-Src. Embo J. 2000, 19: 2911-2923. 10.1093/emboj/19.12.2911PubMedCentralCrossRefPubMed Fincham VJ, James M, Frame MC, Winder SJ: Active ERK/MAP kinase is targeted to newly forming cell-matrix adhesions by integrin engagement and v-Src. Embo J. 2000, 19: 2911-2923. 10.1093/emboj/19.12.2911PubMedCentralCrossRefPubMed
25.
go back to reference Treinies I, Paterson HF, Hooper S, Wilson R, Marshall CJ: Activated MEK stimulates expression of AP-1 components independently of phosphatidylinositol 3-kinase (PI3-kinase) but requires a PI3-kinase signal To stimulate DNA synthesis. Mol Cell Biol. 1999, 19: 321-329.PubMedCentralPubMed Treinies I, Paterson HF, Hooper S, Wilson R, Marshall CJ: Activated MEK stimulates expression of AP-1 components independently of phosphatidylinositol 3-kinase (PI3-kinase) but requires a PI3-kinase signal To stimulate DNA synthesis. Mol Cell Biol. 1999, 19: 321-329.PubMedCentralPubMed
26.
go back to reference McCarthy SA, Samuels ML, Pritchard CA, Abraham JA, McMahon M: Rapid induction of heparin-binding epidermal growth factor/diphtheria toxin receptor expression by Raf and Ras oncogenes. Genes Dev. 1995, 9: 1953-1964.CrossRefPubMed McCarthy SA, Samuels ML, Pritchard CA, Abraham JA, McMahon M: Rapid induction of heparin-binding epidermal growth factor/diphtheria toxin receptor expression by Raf and Ras oncogenes. Genes Dev. 1995, 9: 1953-1964.CrossRefPubMed
27.
go back to reference Clark W, Black EJ, MacLaren A, Kruse U, LaThangue N, Vogt PK, Gillespie DA: v-Jun overrides the mitogen dependence of S-phase entry by deregulating retinoblastoma protein phosphorylation and E2F-pocket protein interactions as a consequence of enhanced cyclin E-cdk2 catalytic activity. Mol Cell Biol. 2000, 20: 2529-2542. 10.1128/MCB.20.7.2529-2542.2000PubMedCentralCrossRefPubMed Clark W, Black EJ, MacLaren A, Kruse U, LaThangue N, Vogt PK, Gillespie DA: v-Jun overrides the mitogen dependence of S-phase entry by deregulating retinoblastoma protein phosphorylation and E2F-pocket protein interactions as a consequence of enhanced cyclin E-cdk2 catalytic activity. Mol Cell Biol. 2000, 20: 2529-2542. 10.1128/MCB.20.7.2529-2542.2000PubMedCentralCrossRefPubMed
28.
go back to reference Kim JW, Lee JE, Kim MJ, Cho EG, Cho SG, Choi EJ: Glycogen synthase kinase 3 beta is a natural activator of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase kinase 1 (MEKK1). J Biol Chem. 2003, 278: 13995-14001. 10.1074/jbc.M300253200CrossRefPubMed Kim JW, Lee JE, Kim MJ, Cho EG, Cho SG, Choi EJ: Glycogen synthase kinase 3 beta is a natural activator of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase kinase 1 (MEKK1). J Biol Chem. 2003, 278: 13995-14001. 10.1074/jbc.M300253200CrossRefPubMed
29.
go back to reference Hetman M, Hsuan SL, Habas A, Higgins MJ, Xia Z: ERK1/2 antagonizes glycogen synthase kinase-3beta-induced apoptosis in cortical neurons. J Biol Chem. 2002, 277: 49577-49584. 10.1074/jbc.M111227200CrossRefPubMed Hetman M, Hsuan SL, Habas A, Higgins MJ, Xia Z: ERK1/2 antagonizes glycogen synthase kinase-3beta-induced apoptosis in cortical neurons. J Biol Chem. 2002, 277: 49577-49584. 10.1074/jbc.M111227200CrossRefPubMed
30.
go back to reference Petropoulos CJ, Givol I, Hughes SH: Comparative analysis of the structure and function of the chicken c-myc and v-myc genes: v-myc is a more potent inducer of cell proliferation and apoptosis than c-myc. Oncogene. 1996, 12: 2611-2621.PubMed Petropoulos CJ, Givol I, Hughes SH: Comparative analysis of the structure and function of the chicken c-myc and v-myc genes: v-myc is a more potent inducer of cell proliferation and apoptosis than c-myc. Oncogene. 1996, 12: 2611-2621.PubMed
31.
32.
go back to reference Bijur GN, De Sarno P, Jope RS: Glycogen synthase kinase-3beta facilitates staurosporine- and heat shock-induced apoptosis. Protection by lithium. J Biol Chem. 2000, 275: 7583-7590. 10.1074/jbc.275.11.7583CrossRefPubMed Bijur GN, De Sarno P, Jope RS: Glycogen synthase kinase-3beta facilitates staurosporine- and heat shock-induced apoptosis. Protection by lithium. J Biol Chem. 2000, 275: 7583-7590. 10.1074/jbc.275.11.7583CrossRefPubMed
33.
go back to reference Gopalbhai K, Meloche S: Repression of mitogen-activated protein kinases ERK1/ERK2 activity by a protein tyrosine phosphatase in rat fibroblasts transformed by upstream oncoproteins. J Cell Physiol. 1998, 174: 35-47. 10.1002/(SICI)1097-4652(199801)174:1<35::AID-JCP5>3.0.CO;2-HCrossRefPubMed Gopalbhai K, Meloche S: Repression of mitogen-activated protein kinases ERK1/ERK2 activity by a protein tyrosine phosphatase in rat fibroblasts transformed by upstream oncoproteins. J Cell Physiol. 1998, 174: 35-47. 10.1002/(SICI)1097-4652(199801)174:1<35::AID-JCP5>3.0.CO;2-HCrossRefPubMed
34.
go back to reference Black EJ, Walker M, Clark W, MacLaren A, Gillespie DA: Cell transformation by v-Jun deactivates ERK MAP kinase signalling. Oncogene. 2002, 21: 6540-6548. 10.1038/sj.onc.1205851CrossRefPubMed Black EJ, Walker M, Clark W, MacLaren A, Gillespie DA: Cell transformation by v-Jun deactivates ERK MAP kinase signalling. Oncogene. 2002, 21: 6540-6548. 10.1038/sj.onc.1205851CrossRefPubMed
35.
go back to reference Gregory MA, Qi Y, Hann SR: Phosphorylation by glycogen synthase kinase-3 controls c-myc proteolysis and subnuclear localization. J Biol Chem. 2003, 278: 51606-51612. 10.1074/jbc.M310722200CrossRefPubMed Gregory MA, Qi Y, Hann SR: Phosphorylation by glycogen synthase kinase-3 controls c-myc proteolysis and subnuclear localization. J Biol Chem. 2003, 278: 51606-51612. 10.1074/jbc.M310722200CrossRefPubMed
36.
go back to reference Sears R, Nuckolls F, Haura E, Taya Y, Tamai K, Nevins JR: Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Genes Dev. 2000, 14: 2501-2514. 10.1101/gad.836800PubMedCentralCrossRefPubMed Sears R, Nuckolls F, Haura E, Taya Y, Tamai K, Nevins JR: Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Genes Dev. 2000, 14: 2501-2514. 10.1101/gad.836800PubMedCentralCrossRefPubMed
37.
go back to reference La Rocca SA, Crouch DH, Gillespie DA: c-Myc inhibits myogenic differentiation and myoD expression by a mechanism which can be dissociated from cell transformation. Oncogene. 1994, 9: 3499-3508.PubMed La Rocca SA, Crouch DH, Gillespie DA: c-Myc inhibits myogenic differentiation and myoD expression by a mechanism which can be dissociated from cell transformation. Oncogene. 1994, 9: 3499-3508.PubMed
38.
go back to reference Gavine PR, Neil JC, Crouch DH: Protein stabilization: a common consequence of mutations in independently derived v-Myc alleles. Oncogene. 1999, 18: 7552-7558. 10.1038/sj.onc.1203102CrossRefPubMed Gavine PR, Neil JC, Crouch DH: Protein stabilization: a common consequence of mutations in independently derived v-Myc alleles. Oncogene. 1999, 18: 7552-7558. 10.1038/sj.onc.1203102CrossRefPubMed
Metadata
Title
Inactivation of MAP kinase signalling in Myc Transformed Cells and Rescue by LiCl inhibition of GSK3
Authors
Osama Al-Assar
Dorothy H Crouch
Publication date
01-12-2005
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2005
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/1476-4598-4-13

Other articles of this Issue 1/2005

Molecular Cancer 1/2005 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine